CORD-19:5e8abc62533a447422d5ead64d4ae4991cc99052 / 1862-2145
Annnotations
CORD-PICO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
p1_all10 | 53-56 | Intervention | denotes | XKB |
p1_all11 | 116-181 | Outcome | denotes | area under the plasma concentration-time curve (AUC) of midazolam |
p1_all12 | 218-267 | Outcome | denotes | plasma clearance and AUC ratio of 1′-OH-midazolam |
p2_i6 | 53-56 | Pharmacological | denotes | XKB |
p2_i7 | 172-181 | Pharmacological | denotes | midazolam |
p2_i8 | 273-282 | Pharmacological | denotes | midazolam |
p2_o11 | 116-181 | Physical | denotes | area under the plasma concentration-time curve (AUC) of midazolam |
p2_o11 | 218-267 | Physical | denotes | plasma clearance and AUC ratio of 1′-OH-midazolam |
CORD-19-Sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T13 | 0-283 | Sentence | denotes | The in vivo study showed that oral administration of XKB at 14 mg/kg to rats for 8 days significantly increased the area under the plasma concentration-time curve (AUC) of midazolam, with a concomitant decrease in the plasma clearance and AUC ratio of 1′-OH-midazolam over midazolam. |
T88805 | 0-283 | Sentence | denotes | The in vivo study showed that oral administration of XKB at 14 mg/kg to rats for 8 days significantly increased the area under the plasma concentration-time curve (AUC) of midazolam, with a concomitant decrease in the plasma clearance and AUC ratio of 1′-OH-midazolam over midazolam. |